Marrone Bio Innovations Appoints Investment Bank co-founder to its Board of Directors
DAVIS, Calif., July 17, 2012 /PRNewswire/ — Marrone Bio Innovations Inc. (MBI), a leading global provider of natural pest management products for the agricultural and water treatment markets, announced today that finance professional and entrepreneur Shaugn Stanley has joined the company’s Board of Directors and will serve as Chairman of the company’s audit committee. One of the founding partners of Thomas Weisel Partners, Stanley brings more than 25 years of financial experience to MBI.
Currently serving as senior managing director at Stifel Financial Corp., which purchased Thomas Weisel Partners in July 2010, Stanley held a number of senior positions including CFO, CAO and Director of Private Client Services during his 12-year tenure at Thomas Weisel Partners. Prior to that, Stanley was CFO at Montgomery Securities and SVP, CFO and Group Risk Manager for Fidelity Investments Brokerage Group in Boston. Stanley began his career as an accountant at Deloitte.
“We are excited to welcome an entrepreneur and leading finance professional such as Shaugn to our board. His unique insight and extensive background in finance and at a start-up himself will be extremely valuable to MBI,” said MBI CEO Pam Marrone.
“I am honored to join the Board of such an exciting and promising company as MBI. With its exceptional products and pipeline, I believe MBI has an opportunity to be a strong leader in the industry, and I look forward to sharing my experiences and contributing to its future success,” said Stanley.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc. is a leading global provider of natural pest management products for the agricultural and water treatment markets. Its effective and environmentally friendly natural agricultural products provide higher yields and quality while managing pesticide resistance and residues. Through its proprietary discovery and development platform and strategically in-licensed technologies, MBI has developed a pipeline of advanced and early-stage products for the significant agricultural and water treatment markets. MBI’s award-winning products for the agricultural market include the biofungicide Regalia®, and Grandevo(TM), a broad-spectrum bioinsecticide for controlling insects and mites. The company also recently received EPA approval of a novel bioherbicide, and has submitted another broad-spectrum insecticide to the EPA that MBI discovered through its screening platform. In addition, MBI is developing at least two nematicides and a fungicide and has several early stage fungicide, algaecide and plant health candidates in the pipeline. MBI is launching the water treatment market with Zequanox®, the industry’s first naturally derived product to selectively control zebra and quagga mussels. MBI currently has more than three-dozen patents pending in the U.S. and globally.
SOURCE Marrone Bio Innovations